Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis vs. Non-Metastasis in Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial

NCT06772363 is registered in ClinicalTrials.gov with Fuzhou General Hospital as lead sponsor.

NCT NCT06772363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06772363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis vs. Non-Metastasis in Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial
Lead sponsor
Fuzhou General Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
April 9, 2026
Completion date
June 1, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancers